ArticleBMC medicine2026
Interpretable multimodal PET/CT-EHR fusion via mixture-of-experts for prognostic stratification in mantle cell lymphoma: a multicenter study.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deep learning-based PET/CT mixture-of-experts model for relapse risk stratification in relapsed/refractory classical hodgkin lymphoma: a multicenter study.European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMantle cell lymphoma (MCL) is a rare, biologically heterogeneous B-cell malignancy with highly variable outcomes. Existing prognostic tools are suboptimal. We developed an interpretable deep learning framework integrating baseline [
methodsIn this multicenter study, 187 treatment-naïve MCL patients were analyzed. A mixture-of-experts (MoE) fusion network integrated multimodal representations from PET/CT and EHR data. Expert modules comprising vision encoders, radiomics extractors, and a medical language model were integrated through an attention-based gating mechanism to construct multimodal radiomic signatures (R-signatures) predictive of progression-free survival (PFS) and overall survival (OS). R-signatures were validated and incorporated with clinical and metabolic factors into multiparametric models. Deep learning model interpretability was evaluated using attention visualization, expert-level contributions and pathologic correlation.
resultsR-signatures robustly discriminated relapse (AUC = 0.893 training, 0.755 validation) and death (AUC = 0.804 and 0.844), and independently predicted adverse outcomes (PFS: HR = 27.70, P < 0.001; OS: HR = 6.86, P = 0.001). Multiparametric models integrating R-signatures with total lesion glycolysis, β2-microglobulin, WBC, and Ki-67 outperformed conventional indices (C-indices: PFS 0.892 training, 0.781 validation; OS 0.877 training, 0.862 validation). Time-dependent ROC analyses consistently showed AUCs approaching or exceeding 0.800. Calibration and decision curve analyses confirmed excellent agreement and superior clinical net benefit. Attention maps localized high-weighted regions to hypermetabolic tumor areas, with higher R-signature values in blastoid and pleomorphic variants versus classical histology (P = 0.028 and P = 0.010).
conclusionsThis interpretable PET/CT-EHR fusion framework substantially improves prognostic precision in MCL, providing a noninvasive, clinically translatable tool for risk-adapted management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.